Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 3Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2

Interventions

Gemcitabine 17pembrolizumab 16Cisplatin 14enfortumab vedotin 7avelumab 7Nivolumab 6Docetaxel 6atezolizumab 5Paclitaxel 5Cystectomy 5sacituzumab govitecan 4durvalumab 4Mitomycin 4Cystoscopy 4Carboplatin 4vofatamab 3tremelimumab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3vinflunine 2tisotumab vedotin 2poly ICLC 2cemiplimab 2aldesleukin 2Transurethral Resection of Bladder 2Radiotherapy, Intensity-Modulated 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Clinical Trials, Phase II as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Urinary Bladder Neoplasms × vinflunine × Clear all
NCT02845050 2018-02-13

JaNEO

Ligartis GmbH

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT01265940 2012-10-10

Pazopanib and Vinflunine in Urothelial Cancer of the Bladder

Lukas-Krankenhaus GmbH

Phase 1/2 Completed
5 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡